Compare Crispr Therapeutics AG (CRSP) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Williams-Sonoma, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.98 (market cap $4.97B), while Williams-Sonoma, Inc. trades at $222.59 (market cap $25.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 5.1× Crispr Therapeutics AG's market cap, and Williams-Sonoma, Inc. pays a 1.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WSM | |
|---|---|---|
Market Cap | $4.97B | $25.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $240.06 |
52-Week Low | $44.34 | $163.62 |
Enterprise Value | $3.32B | $26.35B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Williams-Sonoma (WSM) trades at $216.65, down 2.3% on the day, with a bullish technical outlook supported by moving averages but mixed oscillators. The company demonstrates strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has declined slightly from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten estimates, and the company maintains active brand collaborations and dividend payments.
The stock presents a balanced outlook with solid fundamentals and analyst consensus near the current price, but faces risks from revenue volatility and competitive pressures. Upside potential exists if earnings momentum continues, while macroeconomic headwinds and retail sector challenges pose downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
